Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q1 Revenues Climb

NEW YORK, April 21 (GenomeWeb News) - Luminex revenues increased and its net loss dropped for the first quarter ending March 31, the company reported today.

 

The company reported first-quarter revenues of $9.3 million, compared to $5.1 million for the first quarter of 2003. Net loss for the quarter was $143,000, compared to $906,000 for the year-ago period. The loss excluded $1.8 million for the settlement of a lawsuit, which would have increased the loss to $2.7 million.

 

The company had cash and cash equivalents of $37.5 million on hand as of March 31, down from $39.5 million on Dec. 31.

 

The company spent $958,000 on research and development for the quarter, compared to $831,000 for the same quarter in 2003.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.